Business
Change of Management Team
Change of Management Team.
About this update from Valirx Plc
[{"type":"text","content":"\n \n \n RNS Number : 3940L\n ValiRx PLC\n 30 April 2020\n \n \n \n \n \n \n \n \n \n \n \n \n \n VALIRX PLC\n \n \n (\"ValiRx\", the \"Company\" or the \"Group\")\n \n \n \n \n \n Change of Management Team\n \n \n \n \n \n \n London, UK\n \n ., 30 April 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces that Dr Satu Vainikka and Dr George Morris have ceased to be employees of ValiRx and affiliated companies.\n \n \n \n \n \n On 14 April 2020 the Company announced that Dr Vainikka and Dr Morris were no longer directors of the Company. The Company has now completed the handover procedure.\n \n \n \n \n \n The Board recognise the scientific and commercial contributions provided by Dr Vainikka and Dr Morris and wish them well in future endeavours.\n \n \n \n \n \n -ENDS-\n \n \n \n \n \n This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.\n \n \n \n \n \n \n \n \n For more information, please contact:\n \n \n \n \n \n \n \n \n ValiRx plc\n \n \n \n \n Tel: +44 (0)207 0732628\n \n \n \n www.valirx.com\n \n \n \n \n \n \n \n Kevin Alexander - Non-executive Director\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Cairn Financial Advisers LLP (Nominated Adviser)\n \n \n \n \n Liam Murray / Jo Turner / Ludovico Lazzaretti\n \n \n \n \n \n \n \n Tel: +44 (0) 20 7213 0880\n \n \n \n \n \n \n Peterhouse Capital Limited (Sole Broker)\n \n \n Duncan Vasey / Lucy Williams / Eran Zucker \n \n \n \n \n \n \n \n Tel: +44 (0) 20 7469 0930\n \n \n \n \n \n Notes for Editors\n \n \n \n \n \n About ValiRx \n \n \n ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in \"precision\" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.\n \n \n \n \n \n The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing dis...